Pathology

Medicine & Life Sciences

1. Neoplasms 100%
2. Genes 51%
3. Neoplasm Metastasis 43%
4. Leukemia 36%
5. Indoleamine-Pyrrole 2,3,-Dioxygenase 36%
6. Lymphoma 35%
7. Stem Cells 32%
8. Breast Neoplasms 32%
9. Chromosome Mapping 29%
10. Proteins 28%
11. Receptor, Fibroblast Growth Factor, Type 1 28%
12. Survival 25%
13. Acute Myeloid Leukemia 25%
14. Phosphotransferases 24%
15. Gastric Inhibitory Polypeptide 24%
16. T-Lymphocytes 24%
17. Lung 24%
18. Pathology 23%
19. Therapeutics 23%
20. Urinary Bladder Neoplasms 22%
21. MicroRNAs 22%
22. Glioblastoma 22%
23. Light 21%
24. Kidney 21%
25. Electrophoresis 21%
26. Carcinoma 20%
27. Growth 20%
28. Mutation 20%
29. Phenotype 20%
30. Glioma 19%
31. Biopsy 19%
32. SARS Virus 19%
33. Bone and Bones 18%
34. Prostatic Neoplasms 18%
35. Carcinogenesis 18%
36. Serum 18%
37. Multiple Myeloma 17%
38. Adenocarcinoma 17%
39. Cell Line 16%
40. Staining and Labeling 16%
41. Gene Expression 16%
42. Pediatrics 16%
43. Colorectal Neoplasms 16%
44. Activating Transcription Factor 3 16%
45. Cell Movement 15%
46. spasmolytic polypeptide 15%
47. Pathologists 15%
48. Lymph Nodes 15%
49. Inflammation 15%
50. Apoptosis 15%
51. Antibodies 14%
52. Loss of Heterozygosity 14%
53. Chromosomes 14%
54. Renal Cell Carcinoma 14%
55. Blood Proteins 14%
56. Dendritic Cells 14%
57. Colonic Neoplasms 14%
58. Comparative Genomic Hybridization 13%
59. Melanoma 13%
60. Immunotherapy 13%
61. Myeloid-Derived Suppressor Cells 12%
62. Up-Regulation 12%
63. Neoplastic Stem Cells 12%
64. Zebrafish 12%
65. Cell Proliferation 12%
66. In Vitro Techniques 12%
67. Meningioma 12%
68. Bone Marrow 12%
69. Biomarkers 12%
70. Down-Regulation 12%
71. Brain 11%
72. Genome 11%
73. B-Lymphocytes 11%
74. African Americans 11%
75. Prostate 11%
76. Surgical Pathology 11%
77. Neuroblastoma 11%
78. Squamous Cell Carcinoma 11%
79. DNA 11%
80. Mass Spectrometry 11%
81. Leucine 11%
82. Radiation 10%
83. Seizures 10%
84. Transplants 10%
85. Myeloid Cells 10%
86. Wiskott-Aldrich Syndrome Protein Family 10%
87. Mesenchymal Stem Cells 10%
88. Single Nucleotide Polymorphism 10%
89. Fluorescence In Situ Hybridization 10%
90. Phospholipase D 10%
91. Immunoglobulins 10%
92. Necrosis 10%
93. Drug Therapy 10%
94. Tissue Inhibitor of Metalloproteinase-1 10%
95. Myeloproliferative Disorders 10%
96. Immunohistochemistry 9%
97. Epigenomics 9%
98. DNA Methylation 9%
99. Enzymes 9%
100. Lung Neoplasms 9%